ClinicalTrials.gg
RecruitingNCT07250893RESPONDUpdated Jul 14, 2026

Resolving Early Life Stress: Psychotherapy Outcomes and Neurobiology in Complex Depression

An interventional study of Psychotherapy in Depression - Major Depressive Disorder and Childhood Traumas, sponsored by St. Joseph's Healthcare Hamilton. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by St. Joseph's Healthcare Hamilton · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The RESPOND trial explores the link between early life adversity and later life depressive symptoms. The investigators have designed a new psychological therapy tailored to address the symptoms that can be caused by difficult experiences in early life. These symptoms include low mood, emotional dysregulation, and distressing thoughts and beliefs related to difficult or traumatic experiences. The investigators would like to see if this new therapy helps people feel better. The investigators are also studying the biological changes that can occur as a result of early life adversity, and how this therapy may influence those changes. To do this, the investigators ask questions about participants' physical and mental health and take blood samples.

Read the detailed description

Objectives of proposed study:

  1. Assess efficacy of a novel psychotherapy protocol:

    The investigators will evaluate a new psychotherapy specifically designed to target depressive symptoms and emotional dysregulation in individuals with depressive symptoms and a history of ELA. This protocol incorporates evidence-based techniques from Dialectical Behavior Therapy (DBT), Cognitive Behavioral Therapy (CBT), and Cognitive Processing Therapy (CPT), and is tailored to the unique needs of this population.

  2. Examine biological mechanisms underlying the link between ELA and depression:

To investigate the biological processes that link ELA to later-life depressive pathology, the study will explore epigenetic, inflammatory, and hormonal markers, as well as clinical mechanisms such as trauma-related factors, illness presentation, and comorbid diagnoses.

The primary outcome of this study is a change in depression symptoms as characterized by the Montgomery Åsberg Depression Rating Scale (MADRS). The secondary outcomes will be changes in emotional regulation as measured by the Difficulties in Emotional Regulation Scale (DERS), changes in trauma symptoms as measured by the PTSD Checklist for the DSM-5 (PCL-5) and the International Trauma Questionnaire (ITQ), and changes in inflammation and methylation status as measured through blood analysis.

This study will be run as an open-label, single arm, proof of concept intervention study. The intervention will be run in virtually, 1-on-1, 1x/week for 12 weeks. Participants will undergo a baseline assessment before treatment begins, including biological and clinical measurements; during treatment weekly measures will be administered using the myCap application; more extensive clinical assessments will be done at treatment midpoint (treatment week 6); biological and clinical measurements will be collected at treatment end point (treatment week 12); clinical measures will be collected at a follow-up timepoint (3 months post-treatment).

This study will enroll assigned female at birth (18+) participants with depressive symptoms as measured by the Hamilton Depression Rating Scale (HAM-D) and history of early adversity as indicated by the Childhood Experiences of Care and Abuse questionnaire (CECA q) or the Adverse Childhood Experiences questionnaire (ACES q).

Inclusion:

  • Adults 18 years old or older
  • at or over 18 on HAM-D, indicative of moderate-severe depressive symptoms
  • Any childhood (before 18 years old) adversity as indicated by scores on the CECA q and ACES q

The broad inclusion criteria were chosen in an effort to ensure the study captures a representative sample of people who experience depressive symptoms as a result of early life adversity. The investigators anticipate that some participants will meet criteria for a DSM-5 diagnosis of PTSD or ICD-11 diagnosis of PTSD or complex PTSD, but others will not. This study design will facilitate comparison of participants who develop threshold stress-related disorder symptoms against those who don't on clinical and biological measures, and impairment.

Exclusion:

  • Individuals who meet for PTSD diagnosis from a criterion A trauma occurring in adulthood without a history of ELA

    o Individuals meeting DSM-5 PTSD criteria will be able to get appropriate care through trauma-focused clinics and treatments. Best-evidence treatment for PTSD is a better option for those who meet for a PTSD diagnosis from a criterion A trauma in adulthood (CPT, EMDR, etc.). Additionally, those with criterion A trauma from adulthood may not resonate with the components of the proposed psychotherapy.

  • Individuals experiencing active mania or psychosis
  • Individuals with an active substance use disorder
  • Individuals presenting with active suicide risk (plan, intention, means) indicative of a need for higher level care
  • Individuals in current psychotherapeutic treatment (defined as having engaged in consistent psychotherapy within the last 3 months)

Participants will attend in 4 visits outside of the treatment schedule:

  • Screening visit

    • Can be done either in person or virtually
    • Consent obtained, eligibility assessed and confirmed
    • Information given about structure and content of psychotherapy
  • Baseline visit

    • Must be done in person
    • Diagnostic interview done, blood collected, demographics and medical information collected, and clinical measures administered
  • Treatment endpoint visit (Week 12)

    • Must be done in person
    • Blood collected and clinical measures administered
  • Follow-up appointments

    • Can be done either in person or virtually
    • Clinical measures administered

The psychotherapy intervention was designed by Dr. Sheryl Green, Dr. Jenna Boyd, Dr. Francisco Lima, and Katerina Dikaios. Dr. Sheryl Green is a senior psychologist in the Women's Health Concerns Clinic, a fellow of the Canadian Association of Cognitive and Behavioural Therapies, and has successfully developed multiple novel cognitive behavioural therapy (CBT)-based interventions. Dr. Jenna Boyd is a senior psychologist in the Anxiety Treatment and Research Clinic and an expert in treating specific trauma populations with cognitive behavioural therapy modalities. Dr. Francisco Lima is a psychiatrist in the Women's Health Concerns Clinic, an experienced psychotherapist, and an expert in PTSD and complex trauma. Katerina Dikaios is a PhD candidate in the Psychology Research and Clinical Training program at McMaster University, under the supervision of Drs. Benicio Frey and Sheryl Green; she has an extensive background in psychiatric research including trauma assessment and depression treatment and is currently receiving comprehensive clinical training in cognitive behavioural therapies.

The rationale for this psychotherapy protocol is based on existing evidence suggesting that psychotherapies that prioritize emotional regulation skills before trauma focused therapy appear to garner positive results for individuals who have experienced complex trauma. To date, there has been no investigation of this strategy in individuals with depression. Because complex trauma frequently precedes depressive illness, we have identified this population as an important target for specific psychotherapeutic intervention.

The psychotherapy protocol integrates components from cognitive behavioural therapy (CBT), dialectical behavioural therapy (DBT), and cognitive processing therapy (CPT). The protocol was designed to address common clinical features previously identified in this population, namely low mood, emotional dysregulation, and stuck points related to trauma-related beliefs about oneself and the world. These features map on to ICD-11 cPTSD DSO symptoms clusters of emotional dysregulation (including low mood), negative self-concept, and disturbances in relationships.

Because existing literature has not explored treatment of complex trauma in the context of depressive illness, we tailored this treatment to the population by including aspects of CBT for depression (psychoeducation and behavioural activation) to provide participants with skills to aid in initial alleviation of depressive symptoms. CBT skills is followed by DBT skills hand selected to be applicable for emotional regulation difficulties in this population, along with cognitive processing therapy (CPT) techniques for targeted treatment of trauma-related symptoms.

The psychotherapy intervention will be delivered virtually over 12 weeks, 1x/week for 1 hours, 1-on-1 with a trained therapist. Virtual participation will be held over St. Joe's institutionally licensed Zoom or Teams account.

02

Conditions studied

  • Depression - Major Depressive Disorder
  • Childhood Traumas

Browse trials for

Keywords

  • Early life adversity
  • Depression
  • Emotional dysregulation
  • Childhood trauma
03

In context

Depression

8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.

This study's planned enrollment of 50 is below the median of 81 across 7,063 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

St. Joseph's Healthcare Hamilton is the lead sponsor of 143 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years old or older
  • At or above 18 on HAM-D, indicative of moderate-severe depressive symptoms
  • Any childhood (before 18 years old) adversity as indicated by scores on the CECA q and ACES q

Exclusion criteria

Exclusion Criteria:

  • Individuals who meet for PTSD diagnosis from a criterion A trauma occurring in adulthood without a history of ELA
  • Individuals experiencing active mania or psychosis
  • Individuals with an active substance use disorder
  • Individuals presenting with active suicide risk (plan, intention, means) indicative of a need for higher level care
  • Individuals in current psychotherapeutic treatment (defined as having engaged in consistent psychotherapy within the last 3 months)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Psychotherapy arm

    The psychotherapy intervention will be delivered virtually over 12 weeks, 1x/week for 1 hour, 1-on-1 with a therapist

    Other: Psychotherapy

Interventions

  • OtherPsychotherapy

    Session 1 - Psychoeducation: Introductions + information about adversity and depression Session 2 - Behavioural Activation: Identify activation targets, create Daily Activities Schedule Session 3 - Identifying Emotions: Describe + label emotions; cycle of emotions Session 4 - Distress Tolerance: STOP + TIP skills Session 5 - Distress Tolerance: Self-soothing + improving the moment Session 6 - Stuck Points: Stuck points + impact statements Session 7 - Self-blame Beliefs: Negative self schemas; alternative thoughts worksheet Session 8 - Safety + Trust: Schemas of emotional safety and trust about self and others Session 9 - Power + Control: Stuck points related to scope of influence over events + the world Session 10 - Esteem: Reconstruct ideas of self; engaging positively with others Session 11 - Intimacy: Develop self- and other intimacy behaviours Session 12 - Wrap-up: Review new impact statements; revisit behavioural chang

06

What researchers measure

Primary outcomes

  1. Montgomery and Asberg Depression Rating Scale (MADRS)

    The Montgomery and Asberg Depression Rating Scale is a 10-item semi-structured interview assessing the severity of depressive symptoms (Montgomery \& Åsberg, 1979). The MADRS is sensitive to changes induced my treatment, making it appropriate to implement over psychotherapeutic intervention to monitor changes in depression severity.

    Time frame: Baseline (week 0), Treatment endpoint (week 12), Follow-up (3 months post treatment)

Secondary outcomes

  1. Difficulties with Emotional Regulation Scale

    The Difficulties with Emotional Regulation Scale is a self-report measure used to assess emotional regulation difficulties over multiple domains (Gratz \& Roemer, 2004). It is a transdiagnostic measure appropriate for measuring changes in emotional regulation over time.

    Time frame: Baseline (week 0), Treatment endpoint (week 12), Follow-up (3 months post treatment)

  2. International Trauma Questionnaire

    The International Trauma Questionnaire is a self-report measure designed to assess and diagnose PTSD and complex PTSD in accordance with criteria from the ICD-11 (Cloitre, 2020; Cloitre et al., 2018). The questionnaire also measures symptom severity for PTSD and cPTSD symptom clusters. It is the only self-report measure designed to diagnose ICD-11 cPTSD.

    Time frame: Baseline (week 0), Treatment endpoint (week 12), Follow-up (3 months post treatment)

  3. PTSD Checklist for the DSM-5

    The PTSD Checklist for the DSM-5 is a self-report measure used to assess the severity of PTSD symptoms as identified by the DSM-5 (American Psychiatric Association, 2013; Blevins et al., 2015). The measure is appropriate for evaluating treatment progress and changes in PTSD symptoms over time.

    Time frame: Baseline (week 0), Treatment endpoint (week 12), Follow-up (3 months post treatment)

  4. Biomarkers - Hormonal markers

    Neurosteroid markers in the allopragnanolone pathway

    Time frame: Baseline (week 0), Treatment endpoint (week 12)

  5. Illness Intrusiveness Scale

    The Illness Intrusiveness Scale is a 13-item self-report questionnaire assessing the impact of chronic illnesses such as mental illness on a person's daily life, functioning, and well-being (Fattori et al., 2016). The Illness Intrusiveness Scale covers three domains: relationships and personal development, instrumental life domains, and intimacy and leisure.

    Time frame: Baseline (week 0), Treatment endpoint (week 12), Follow-up (3 months post treatment)

  6. Biomarkers - Epigenetic

    DNA methylation (epigenetic) markers: SLC6A4, which plays a crucial role in serotonin transportation; FKBP5, which is implicated in cortisol signalling; brain derived neurotrophic factor (BDNF), which supports neuronal growth, maturation, and maintenance; NR3C1, which codes for glucocorticoid receptors and regulates the HPA axis.

    Time frame: Baseline (week 0), Treatment endpoint (week 12)

  7. Biomarkers - Inflammatory

    Inflammatory markers: CRP, which provides a proxy measurement for overall immune functioning; interleukin 6 (IL-6), a cytokine playing both pro- and anti-inflammatory roles; interferon-gamma (IFN-g), a pro-inflammatory cytokine; interleukin-10 (IL-10), an anti-inflammatory cytokine; tumor necrosis factor-alpha (TNF-a), another pro-inflammatory cytokine.

    Time frame: Baseline (week 0), Treatment endpoint (week 12)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 21 months after the start.

Of 3,468 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 21 months is close to that.

Counting every sponsor, half of 3,566 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Nov 26, 2025
StartActual
Oct 25, 2025
Primary completionEst.
Aug 15, 2027
CompletionEst.
Aug 15, 2028
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07250893
Collaborators
Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Responsible party
Benicio Frey (Professor, Psychiatry & Behavioural Neurosciences; Director, Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, St. Joseph's Healthcare Hamilton) — Principal investigator
First posted
Nov 26, 2025
Start date
Oct 25, 2025
Primary completion
Aug 15, 2027 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

Katerina Dikaios, MSc
Contact
dikaiosk@mcmaster.ca
905 522 1155 ext. 39110
Benicio Frey, MD, PhD
principal investigator · St. Joseph's Healthcare Hamilton
Sheryl Green, PhD
principal investigator · St. Joseph's Healthcare Hamilton
Jenna Boyd, PhD
principal investigator · St. Joseph's Healthcare Hamilton

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion